Integra LifeSciences Schedules Conference Call for Thursday, August 2 to Discuss Second Quarter 2001 Results and Financial Outlook
The conference call has been rescheduled for 9:00 am EST on Thursday, August 2, 2001. The call had previously been scheduled for Wednesday, August 8. Financial results for the second quarter 2001 will be announced via a news release issued before the market opens on August 2.
The call will be hosted by Stuart Essig, President and Chief Executive Officer of Integra, and is open to all listeners. There will be no question and answer session after the call. Forward-looking guidance will be provided for anticipated growth in product sales, total revenues and operating costs along with a range for earnings per share estimates.
Access to the live call is available by dialing 877/691-0877 in the United States or 973/628-9554 for international listeners or through a webcast which can be accessed via a link provided on the home page of Integra's website at www.Integra-LS.com.
Integra's conference call will be available for replay starting one hour following the live event. Access to the replay of the conference call is available through August 16, 2001 by dialing 877/519-4471 in the United States or 973/341-3080 for international listeners (pin code 2666480) or through a webcast which can be accessed via a link provided on the home page of Integra's website.
Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of spinal and cranial disorders, soft-tissue repair and orthopedics. The Company has its headquarters in Plainsboro, New Jersey and has approximately 550 permanent employees. Please visit the Company's website at http://www.Integra-LS.com.
Statements made in the upcoming conference call may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results.
Forward-looking factors that may be discussed include, but are not limited to, expected financial results, new product development, governmental approvals, market potential, expected sales and potential therapeutic applications of new products, new sources of potential financing and additional acquisitions.
In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K/A for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Source: Integra LifeSciences Holdings Corporation
www.integra-LS.com
CONTACT: Integra LifeSciences Holdings Corporation
John Bostjancic, 609/936-2239
jbostjancic@integra-ls.com